Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging
- 1 March 2006
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Endocrinology & Metabolism
- Vol. 2 (3), 146-159
- https://doi.org/10.1038/ncpendmet0120
Abstract
Testosterone use as anabolic therapy is controversial. Here, meta-analyses show that testosterone increases skeletal muscle mass and strength in androgen-deficient young men, older men and men with chronic illness; these data provide a compelling rationale for the development of selective androgen receptor modulators that mimic testosterone's effects without its side effects. Several regulatory concerns have hindered development of androgens as anabolic therapies, despite unequivocal evidence that testosterone supplementation increases muscle mass and strength in men; it induces hypertrophy of type I and II muscle fibers, and increases myonuclear and satellite cell number. Androgens promote differentiation of mesenchymal multipotent cells into the myogenic lineage and inhibit their adipogenic differentiation, by facilitating association of androgen receptors with β-catenin and activating T-cell factor 4. Meta-analyses indicate that testosterone supplementation increases fat-free mass and muscle strength in HIV-positive men with weight loss, glucocorticoid-treated men, and older men with low or low-normal testosterone levels. The effects of testosterone on physical function and outcomes important to patients have not, however, been studied. In older men, increased hematocrit and increased risk of prostate biopsy and detection of prostate events are the most frequent, testosterone-related adverse events. Concerns about long-term risks have restrained enthusiasm for testosterone use as anabolic therapy. Selective androgen-receptor modulators that are preferentially anabolic and that spare the prostate hold promise as anabolic therapies. We need more studies to determine whether testosterone or selective androgen-receptor modulators can induce meaningful improvements in physical function and patient-important outcomes in patients with physical dysfunction associated with chronic illness or aging.Keywords
This publication has 85 references indexed in Scilit:
- Structural basis for antagonism and resistance of bicalutamide in prostate cancerProceedings of the National Academy of Sciences, 2005
- Principles for modulation of the nuclear receptor superfamilyNature Reviews Drug Discovery, 2004
- Testosterone Versus Fluoxetine for Depression and Fatigue in HIV/AIDSJournal of Clinical Psychopharmacology, 2004
- Pharmacokinetics ofS-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro- 3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgen receptor modulatorXenobiotica, 2004
- Electrostatic Modulation in Steroid Receptor Recruitment of LXXLL and FXXLF MotifsMolecular and Cellular Biology, 2003
- Defining the "S" in SERMsScience, 2002
- Prevalence of Hypogonadism among Men with Weight Loss Related to Human Immunodeficiency Virus Infection Who Were Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2000
- Effect of Testosterone and Estradiol in a Man with Aromatase DeficiencyNew England Journal of Medicine, 1997
- The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal MenNew England Journal of Medicine, 1996
- Regulation and compartmentalization ofandrogens in rat prostate and muscleJournal of Steroid Biochemistry, 1983